F D C

F D C EBIT per Employee

The EBIT per Employee of F D C (FDC.NS) as of Nov 1, 2026 is 425,402.39 INR. In the previous year, EBIT per Employee was 468,645.64 INR — a change of -9.23% (lower).

EBIT per Employee

425,402.39INR

YoY

-9.23%

Last updated:

EBIT per Employee of F D C is 2025 425,402.39 INR. EBIT per Employee of F D C was 2024 468,645.64 INR. It decreases by -9.23% lower compared to the previous year.

The F D C EBIT per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Employee
Date
EBIT per Employee
Jan 1, 2018
310,577.53 INR
Jan 1, 2019
308,634.81 INR
Jan 1, 2020
460,742.31 INR
Jan 1, 2021
461,574.86 INR
Jan 1, 2022
339,586.79 INR
Jan 1, 2023
332,760.51 INR
Jan 1, 2024
468,645.64 INR
Jan 1, 2025
425,402.39 INR
The F D C EBIT per Employee history
YEAREBIT per EmployeeYoY
425,402.39INR-9.23%
468,645.64INR+40.84%
332,760.51INR-2.01%
339,586.79INR-26.43%
461,574.86INR+0.18%
460,742.31INR+49.28%
308,634.81INR-0.63%
310,577.53INR-2.49%
318,514.12INR+4.07%
306,044.57INR+21.72%
251,427.34INR-12.23%
286,448.05INR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

F D C Stock analysis

What does F D C do? FDC Ltd. generates revenue through the manufacturing and distribution of pharmaceutical generics, formulations, and active pharmaceutical ingredients (APIs). The company produces specialized products such as oral rehydration salts (ORS) and functional foods and beverages, targeting therapeutic segments including anti-infectives, gastrointestinal, ophthalmological, vitamins/minerals/dietary supplements, cardiac, anti-diabetes, respiratory, gynecology, dermatology, and analgesics. Its branded products like Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zoxan, Zathrin, Zipod, Zefu, Cotaryl, and Mycoderm are sold to healthcare providers and consumers across these segments. The company's APIs, including Albuterol Sulfate, Bromhexine Hydrochloride, Cinnarizine, Flunarizine Dihydrochloride, Flurbiprofen, Flurbiprofen Sodium, Miconazole Nitrate, and Timolol Maleate, support its formulation business. FDC Ltd. distributes its products through its manufacturing plants, serving both domestic and international markets with a focus on cost-effective generic medicines and specialized formulations. FDC Ltd. targets healthcare providers, hospitals, and retail pharmacies as key buyers of its branded pharmaceuticals and functional products. The company's product portfolio spans multiple therapeutic areas, with brands like Zifi for respiratory conditions and Electral for rehydration, catering to diverse consumer needs in the Indian pharmaceutical market. F D C is one of the most popular companies on Eulerpool.

Frequently Asked Questions about F D C stock

EBIT per Employee of F D C is 425,402.39 INR in 2025.

EBIT per Employee of F D C changed from 468,645.64 INR to 425,402.39 INR, representing a -9.23% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Employee F D C since 2006 – with annual values, charts, and detailed analysis.

EBIT per employee measures operating profit per employee, showing how efficiently the workforce generates operating earnings.

EBIT per Employee's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT per Employee's F D C historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — F D C

All Key Metrics — F D C